Biora Therapeutics, Inc. (BIOR)

Biora Therapeutics, Inc. (BIOR) Healthcare & Pipeline Overview

Biora Therapeutics, Inc. is a biotechnology firm pioneering oral biotherapeutics through ingestible smart capsules for targeted gastrointestinal delivery, addressing inflammatory bowel diseases and systemic drug uptake. The company also develops innovative diagnostic devices for GI tract characterization and disease diagnosis, positioning itself in the evolving precision medicine landscape.

What Is the Investment Thesis for BIOR?

Biora Therapeutics, Inc. is positioned within the biotechnology sector with a distinct focus on addressing unmet needs in gastrointestinal (GI) health through innovative oral biotherapeutics and diagnostic devices. The company's core value proposition lies in its proprietary ingestible smart capsule technology, which offers targeted delivery for inflammatory bowel diseases (IBD) and needle-free systemic delivery of biotherapeutics. This innovative approach, particularly the NaviCap platform, represents a potential paradigm shift in drug administration, promising improved patient compliance and potentially enhanced therapeutic efficacy by reducing systemic exposure and side effects. Financially, the company exhibits a 100.0% gross margin, which, while indicative of its early-stage, R&D-heavy operations with minimal cost of goods sold, is juxtaposed with a significant negative profit margin of -3102875.0%, underscoring its current investment phase. Key growth catalysts include successful progression through clinical trials for its targeted and systemic therapeutics programs, achieving regulatory milestones for its diagnostic devices, and potential future financing activities to support its pipeline. However, investors must consider the inherent risks associated with biotechnology development, including clinical trial outcomes, regulatory approvals, and the challenges of operating on the OTC Other tier, which implies limited liquidity and heightened volatility, as reflected by its Beta of 1.28.

Based on FMP financials and quantitative analysis

BIOR Key Highlights

• Biora Therapeutics operates with a Market Cap of $0.00B, indicating a very small market valuation, often characteristic of early-stage development companies.
• The company reports a Gross Margin of 100.0%, which suggests that, at its current stage, it has minimal or no direct costs associated with revenue generation, typical for R&D-focused biotech firms.
• A significant Profit Margin of -3102875.0% highlights substantial operational losses, reflecting the intensive research and development investments required in the biotechnology industry.
• Biora Therapeutics' Beta of 1.28 indicates higher volatility compared to the broader market, a common trait for small-cap biotechnology stocks with binary clinical trial outcomes.
• The company's core focus is on developing innovative oral biotherapeutics and diagnostic devices for gastrointestinal diseases, leveraging proprietary ingestible capsule technologies.

Who Are BIOR's Competitors?

BIOR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BIOR's Key Strengths?

• Innovative targeted drug delivery platform (NaviCap) using ingestible smart capsules for GI diseases.
• Development of needle-free systemic biotherapeutic delivery, potentially improving patient compliance.
• Focus on developing diagnostic devices for on-site GI disease characterization and diagnosis.
• High gross margin of 100.0% reflects an R&D-heavy, pre-commercial business model with potential for future profitability if products succeed.

What Are BIOR's Weaknesses?

• Market capitalization of $0.00B indicates a very small or negligible valuation, typical for early-stage companies.
• Significant negative profit margin of -3102875.0% highlights substantial ongoing losses and reliance on external financing.
• Trading on the OTC Other tier, which implies limited liquidity, heightened volatility, and potentially less investor transparency.
• Early-stage development with no commercial products, leading to inherent risks associated with clinical trials and regulatory approvals.

What Could Drive BIOR Stock Higher?

• Positive clinical trial results for its targeted therapeutics program, demonstrating efficacy and safety in inflammatory bowel diseases.
• Achievement of key regulatory milestones, such as Investigational New Drug (IND) application acceptance or Fast Track designation, for its therapeutic candidates.
• Successful progression of its diagnostic devices through development and regulatory pathways, leading to market clearance or approval.
• Continued development and refinement of the NaviCap targeted oral delivery platform, potentially expanding its applications.
• Future financing activities that successfully secure capital to advance its pipeline without excessive dilution, as noted in AI insights.

What Are the Key Risks for BIOR?

• Significant negative profit margin of -3102875.0% indicates substantial cash burn and reliance on external funding for operations.
• Early-stage nature of its product pipeline means there are no commercial products generating revenue, posing high R&D and commercialization risks.
• Clinical trial failures or delays for its oral biotherapeutics, which could significantly impact the company's valuation and future prospects.
• Regulatory hurdles and challenges in gaining approval for novel drug delivery systems and diagnostic devices from health authorities.
• Risks associated with trading on the OTC Other tier, including limited liquidity, heightened volatility, and potential difficulty in raising capital.
• Intense competition from larger pharmaceutical companies and other biotech firms with more resources and established market presence.

What Are the Growth Opportunities for BIOR?

• Growth opportunity 1: **Advancement of Targeted Oral Delivery for Inflammatory Bowel Diseases (IBD)**. Biora's ingestible smart capsule for targeted delivery of therapeutics in the GI tract represents a significant opportunity. The global IBD market is substantial, driven by increasing prevalence and the need for more effective, localized treatments. By precisely delivering drugs to inflamed areas, this technology could enhance efficacy, reduce systemic side effects, and improve patient adherence compared to conventional systemic therapies. Successful progression through clinical trials and eventual commercialization could capture a meaningful share of this market by offering a differentiated and potentially superior treatment option.
• Growth opportunity 2: **Expansion of Systemic Needle-Free Biotherapeutic Delivery**. The company's ingestible capsule designed for needle-free delivery of biotherapeutics directly into the intestinal mucosa offers a compelling alternative to injectable drugs. This innovation could significantly improve patient convenience and compliance, particularly for chronic conditions requiring frequent administration. The market for biotherapeutics is vast and growing, and a successful oral, needle-free delivery platform could unlock access to a broader patient population and a wider range of therapeutic molecules, potentially disrupting segments of the injectable drug market by offering a more patient-friendly option.
• Growth opportunity 3: **Development and Commercialization of GI Diagnostics Devices**. Biora's focus on developing diagnostic devices to characterize the GI tract and diagnose diseases like small intestine bacterial overgrowth (SIBO) presents a distinct growth avenue. Accurate and timely diagnosis at the site of disease can lead to more effective treatment strategies and improved patient outcomes. The market for advanced GI diagnostics is expanding, driven by increasing awareness of gut health and the demand for non-invasive, precise diagnostic tools. Successful development and market adoption of these devices could establish Biora as a comprehensive solution provider in GI health, complementing its therapeutic pipeline.
• Growth opportunity 4: **Leveraging the NaviCap Targeted Oral Delivery Platform**. The NaviCap platform, highlighted as a primary focus, represents a foundational technology with potential for broader application beyond its initial targets. While currently focused on IBD, the underlying technology of an ingestible smart capsule for precise GI delivery could be adapted for other gastrointestinal conditions, or even for the delivery of other types of therapeutics that benefit from localized or enhanced systemic uptake via the GI tract. Further development and strategic expansion of the platform's capabilities could unlock additional therapeutic areas and market opportunities over time.
• Growth opportunity 5: **Addressing Unmet Needs in Gastrointestinal Health**. Biora Therapeutics' overall strategy is centered on addressing significant unmet medical needs in both the treatment and diagnosis of GI diseases. The chronic and often debilitating nature of conditions like IBD, coupled with the challenges of current drug delivery methods, creates a substantial market for innovative solutions. By developing novel oral biotherapeutics and advanced diagnostic tools, Biora aims to improve patient quality of life and clinical outcomes. Successfully bringing these solutions to market would tap into a large patient population seeking more effective, convenient, and less invasive options for managing their GI health.

What Opportunities Does BIOR Have?

• Successful progression and positive outcomes from clinical trials for its targeted and systemic therapeutics programs.
• Potential for regulatory approvals and commercialization of its innovative drug delivery systems and diagnostic devices.
• Expansion of the NaviCap platform's application to a broader range of GI conditions or other therapeutic areas.
• Addressing a large and growing market for gastrointestinal therapeutics and diagnostics with unmet patient needs.

What Threats Does BIOR Face?

• Risk of clinical trial failures, delays, or unfavorable results for its therapeutic candidates.
• Challenges in obtaining regulatory approvals for novel drug delivery systems and diagnostic devices.
• Intense competition from established pharmaceutical companies and other biotechnology firms in GI health.
• Ongoing need for significant financing to fund R&D and operational expenses, with potential for dilution.
• Risks associated with the OTC Other market, including difficulty in raising capital, price manipulation, and lack of investor interest.

What Are BIOR's Competitive Advantages?

• Proprietary ingestible smart capsule technology for targeted delivery of therapeutics within the gastrointestinal (GI) tract, offering precision and potentially reduced systemic side effects.
• Proprietary ingestible capsule system designed for needle-free delivery of biotherapeutics directly into the intestinal mucosa, enhancing systemic uptake and patient convenience.
• Development of unique diagnostic devices for on-site characterization and diagnosis of GI diseases, providing a differentiated approach to GI health management.
• Focus on addressing specific unmet medical needs in GI therapeutics and diagnostics, potentially creating a first-mover advantage in certain niche applications.
• Intellectual property surrounding its innovative drug delivery platforms and diagnostic technologies, which could create barriers to entry for competitors.

What Does BIOR Do?

Biora Therapeutics, Inc., headquartered in San Diego, California, is a biotechnology company established in 2010, initially operating as Progenity, Inc. The company underwent a strategic rebranding in April 2022, changing its name to Biora Therapeutics, Inc. to more accurately reflect its sharpened focus on its therapeutics pipeline. Biora Therapeutics is dedicated to advancing oral biotherapeutics through innovative delivery mechanisms. Its core strategy revolves around two primary programs: targeted therapeutics and systemic therapeutics, alongside a commitment to developing advanced diagnostic devices for gastrointestinal health. The targeted therapeutics program utilizes an ingestible smart capsule designed for precise delivery of therapeutic agents within the gastrointestinal (GI) tract. This technology aims to significantly enhance the treatment efficacy for inflammatory bowel diseases (IBD) by ensuring that medication reaches the affected areas directly, potentially minimizing systemic side effects and improving patient outcomes. Concurrently, the systemic therapeutics program employs a different ingestible capsule engineered for needle-free delivery of biotherapeutics directly into the intestinal mucosa. This approach is intended to facilitate enhanced systemic uptake of drugs, offering a less invasive and potentially more patient-friendly alternative to traditional injectable biotherapeutics. Beyond therapeutics, Biora Therapeutics is also actively engaged in the development of sophisticated diagnostic devices. These devices are designed to aid in the comprehensive characterization of the GI tract and the accurate diagnosis of various GI diseases, including conditions such as small intestine bacterial overgrowth (SIBO). By developing technologies that enable diagnosis at the site of the disease, Biora aims to provide more precise and timely information for clinical decision-making, thereby complementing its therapeutic development efforts and offering a holistic approach to gastrointestinal health management. The company operates with a team of 58 employees, driving its research and development initiatives.

What Products and Services Does BIOR Offer?

• Develops oral biotherapeutics using advanced delivery systems.
• Utilizes ingestible smart capsules for targeted delivery of therapeutics in the gastrointestinal (GI) tract.
• Focuses on enhancing the treatment of inflammatory bowel diseases (IBD) with precision delivery.
• Designs ingestible capsules for needle-free delivery of biotherapeutics directly into the intestinal mucosa.
• Aims for enhanced systemic uptake of biotherapeutics through its needle-free delivery system.
• Develops diagnostic devices to characterize the GI tract and diagnose GI diseases.
• Creates technologies to diagnose conditions like small intestine bacterial overgrowth (SIBO) at the site of the disease.
• Operates as a biotechnology company, formerly known as Progenity, Inc.

How Does BIOR Make Money?

• Primarily focused on research and development (R&D) of proprietary oral biotherapeutics and diagnostic devices.
• Future revenue generation is anticipated from the commercialization and sales of its developed therapeutic products.
• Potential for revenue streams from licensing agreements for its proprietary drug delivery platforms or diagnostic technologies.
• Future revenue may also come from the sales of its diagnostic devices to healthcare providers and laboratories.
• Currently in a pre-commercial stage, with significant investment in clinical trials and product development.

What Industry Does BIOR Operate In?

Biora Therapeutics, Inc. operates within the dynamic and innovation-driven biotechnology industry, a sub-sector of Healthcare. This industry is characterized by extensive research and development efforts aimed at discovering, developing, and commercializing novel therapeutic and diagnostic solutions. Biora's specific niche involves addressing gastrointestinal (GI) diseases, particularly inflammatory bowel diseases (IBD), and improving systemic drug delivery through advanced oral methods. The broader GI therapeutics market is substantial, driven by the increasing prevalence of chronic conditions like IBD and the ongoing need for more effective and patient-friendly treatment options. The company's focus on targeted oral delivery and needle-free systemic administration positions it within a segment seeking to overcome limitations of traditional drug delivery, such as poor bioavailability, systemic side effects, and patient compliance issues. The competitive landscape includes established pharmaceutical companies with existing GI portfolios, as well as numerous other biotech firms developing novel drugs and drug delivery technologies. Biora's success will depend on its ability to differentiate its proprietary ingestible smart capsule technology and diagnostic devices in a crowded and highly regulated market.

Who Are BIOR's Key Customers?

• Patients suffering from inflammatory bowel diseases (IBD) who require targeted therapeutic interventions.
• Patients needing systemic delivery of biotherapeutics, particularly those seeking needle-free and convenient administration.
• Individuals requiring diagnosis and characterization of gastrointestinal (GI) diseases, such as small intestine bacterial overgrowth (SIBO).
• Healthcare providers, including gastroenterologists and other specialists, who would prescribe or utilize Biora's therapeutic and diagnostic products.
• Hospitals and clinics that would integrate Biora's diagnostic devices into their clinical workflows.

Company Profile

Biora Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Aditya Mohanty. BIOR has traded publicly since 2020.

Biora Therapeutics, Inc. Financial Trajectory

Biora Therapeutics, Inc. (BIOR) reported $32K in revenue for Q3 2024, a decline of 89.9% compared to the prior quarter. The company recorded a net loss of $18.4M, with diluted EPS of $-5.04. Revenue has contracted over three consecutive quarters, which investors in this unknown Healthcare stock should monitor closely.

How Biora Therapeutics, Inc. Is Valued

Relative to its peer group, BIOR's quantitative score of 56/100 is below the peer average of 76/100.

ROE 122%Key Financial Metrics

Return on equity for Biora Therapeutics, Inc. stands at 121.9%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.30 means current liabilities exceed short-term assets, a liquidity point worth watching.

F-Score 4/9Financial Health

Biora Therapeutics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.

FY2026 estForward Outlook

Wall Street analysts project Biora Therapeutics, Inc. revenue of about $5.5M for fiscal 2026, with EPS near $-3.32.

BIOR Financials

BIOR Latest News

BIOR Analyst Consensus

BIOR MoonshotScore

Common Questions About BIOR (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources